Investigators are testing new experimental drug combinations such as the combination of
vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may
be effective against tumors that have come back or that have not responded to standard
The goals of this study are:
To find the highest safe dose of vorinostat that can be given together with vincristine,
irinotecan, and temozolomide without causing severe side effects;
To learn what kind of side effects this four drug combination can cause;
To learn about the effects of vorinostat and the combination of vorinostat, vincristine,
irinotecan, and temozolomide on specific molecules in tumor cells;
To determine whether the combination of vorinosat, vincristine, irinotecan, and
temozolomide is a beneficial treatment.
This first cycle will be used to determine whether the patient can tolerate the
chemotherapeutic backbone without developing a DLT. The baseline disease evaluation will be
obtained following hematologic recovery from the first cycle of chemotherapy, after which
combination therapy with vorinostat will be given in subsequent cycles (2-12) w/
modifications if needed. Vorinostat dose escalation in subsequent patient cohorts will occur
based on DLT to determine a MTD.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.